Study on Abiraterone Acetate or Enzalutamide, Atezolizumab, Hormone Therapy, and Radiation for Men with Newly Diagnosed Hormone-Sensitive Prostate Cancer

Inclusion Criteria

• Men aged 18 and older.
• Have metastatic prostate cancer that is sensitive to hormones and has not been treated before.
• Have a biopsy-confirmed diagnosis of prostate adenocarcinoma.
• Eligible for targeted radiation therapy (SBRT) based on medical guidelines.
• Have a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Normal organ function and acceptable lab results within 14 days before starting treatment.
• Agree to use effective birth control methods during the study and for 150 days after the last dose of the study drug.
• Willing to provide informed consent and authorization for the release of personal health information.

Exclusion Criteria

• History of another cancer within the last 3 years, except for certain skin cancers.
• Prostate cancer with a specific type of cell (small cell carcinoma).
• Prostate volume greater than 80 cc.
• Known or suspected brain metastasis or active disease in the brain or spinal fluid.
• Uncontrolled pain related to the tumor.
• Uncontrolled fluid buildup around the lungs, heart, or abdomen.
• Uncontrolled high blood pressure.
• Positive HIV test or active hepatitis B or C infection.
• History of adrenal gland problems.
• Uncontrolled high calcium levels in the blood.
• Active or history of autoimmune diseases or immune deficiencies, with some exceptions.
• History of certain lung diseases or active lung inflammation.
• Active tuberculosis.
• Significant heart disease within the last 6 months.
• Major surgery within 4 weeks before starting the study.
• Severe infection within 4 weeks before starting the study.
• Previous organ or stem cell transplant.
• Recent treatment with live vaccines, certain antibiotics, or investigational therapies.
• Previous treatment with specific immune therapies or immune-stimulating drugs.
• Use of systemic immunosuppressive medications recently or during the study, with some exceptions.
• Severe allergic reactions to certain antibodies or components of the study drugs.
• Any other condition that could interfere with the study or pose a risk to the participant.